238 related articles for article (PubMed ID: 25655791)
1. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.
Bejanyan N; Rogosheske J; DeFor T; Lazaryan A; Esbaum K; Holtan S; Arora M; MacMillan ML; Weisdorf D; Jacobson P; Wagner J; Brunstein CG
Biol Blood Marrow Transplant; 2015 May; 21(5):926-33. PubMed ID: 25655791
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
Bejanyan N; Rogosheske J; DeFor TE; Lazaryan A; Arora M; Holtan SG; Jacobson PA; MacMillan ML; Verneris MR; Blazar BR; Weisdorf DJ; Wagner JE; Brunstein CG
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2025-2030. PubMed ID: 27519278
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.
Miyamoto T; Takashima S; Kato K; Takase K; Yoshimoto G; Yoshida S; Henzan H; Osaki K; Kamimura T; Iwasaki H; Eto T; Teshima T; Nagafuji K; Akashi K
Int J Hematol; 2017 Jan; 105(1):92-99. PubMed ID: 27686673
[TBL] [Abstract][Full Text] [Related]
4. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
6. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
Harnicar S; Ponce DM; Hilden P; Zheng J; Devlin SM; Lubin M; Pozotrigo M; Mathew S; Adel N; Kernan NA; O'Reilly R; Prockop S; Scaradavou A; Hanash A; Jenq R; van den Brink M; Giralt S; Perales MA; Young JW; Barker JN
Biol Blood Marrow Transplant; 2015 May; 21(5):920-5. PubMed ID: 25687796
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
8. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
13. Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation.
Bejanyan N; Rogosheske J; Cao Q; Lazaryan A; Holtan S; Ustun C; Jacobson P; MacMillan M; Weisdorf DJ; Wagner J; Arora M; Brunstein CG
Eur J Haematol; 2021 Feb; 106(2):205-212. PubMed ID: 33084139
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
15. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
Yoshida S; Ohno Y; Nagafuji K; Yoshimoto G; Sugio T; Kamimura T; Ohta T; Takase K; Henzan H; Muta T; Iwasaki H; Ogawa R; Eto T; Akashi K; Miyamoto T
Ann Hematol; 2019 Nov; 98(11):2579-2591. PubMed ID: 31628517
[TBL] [Abstract][Full Text] [Related]
16. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
[TBL] [Abstract][Full Text] [Related]
17. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
19. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
Kasper C; Sayer HG; Mügge LO; Schilling K; Scholl S; Issa MC; Höffken K
Bone Marrow Transplant; 2004 Jan; 33(1):65-9. PubMed ID: 14704658
[TBL] [Abstract][Full Text] [Related]
20. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
